In:
Clinical Transplantation, Wiley, Vol. 23, No. 3 ( 2009-06), p. 431-434
Abstract:
Abstract: We report on the reactivation of hepatitis B in a renal transplant patient who had been treated with rituximab for recurrent focal segmental glomerulosclerosis two and a half yr previously. He lost his anti‐hepatitis B surface antigens and anti‐hepatitis B core antigen antibodies and developed hepatitis B virus (HBV)‐DNA positive hepatitis. Hepatitis C, which had been successfully treated by alpha interferon 10 yr before, remained quiescent. We suggest regular controls of HBV‐DNA, anti‐HBV antibodies and transaminases for prolonged periods in patients with status post‐hepatitis B treated with rituximab. Prophylactic therapy with lamivudine and/or hepatitis B hyperimmune globulin may be considered in patients with a decrease in anti‐HBV antibodies.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2009.23.issue-3
DOI:
10.1111/j.1399-0012.2008.00936.x
Language:
English
Publisher:
Wiley
Publication Date:
2009
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Bookmarklink